Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...

After registering a net profit of Rs 25.1 crore in Q3FY25 and consolidated revenues growing by 7 per cent on a like-for-like ...

Much like liraglutide, tirzepatide is also currently only available in an injectable form. GLP-1-H24-3 was an 8 patient - 2 arm - single dose - cross-over study. The 2 arms included an injectable ...

Much like liraglutide, tirzepatide is also currently only available in an injectable form. GLP-1-H24-3 was an 8 patient - 2 arm - single dose - cross-over study. The 2 arms included an injectable ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

GLP-1 agonists for weight loss are now commonly used for adults, but might they also be an effective treatment for younger people? Katharine Lang reports Obesity in children and adolescents is a ...

Nanexa AB announces that the phase I study with NEX-22, the company's one-month formulation of liraglutide, will resume with further dose escalation with an expected start in the first quarter of ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

Victoza is the first and (as of December 2024) only GLP-1 agonist available as a generic. Administration and Dosage All GLP-1 agonists, including Victoza and Ozempic, are given by subcutaneous (under ...